The purpose of this research is to evaluate how safe DYNE-101 is and how well patients tolerate it when given multiple doses. The study will also examine how the medication affects muscle tissue in people with Myotonic Dystrophy Type 1. The medication being tested is a specially designed antibody that targets specific proteins in the body.

During the study, participants will receive multiple doses of either DYNE-101 or placebo through an intravenous line. The study will involve various assessments of muscle strength and function, including tests of hand grip strength and walking ability. Participants will also undergo muscle tissue sampling to evaluate how the medication affects their muscle cells.

During the study, participants will receive either the active medication or a placebo. The treatment lasts for 48 weeks. While receiving the treatment, various observations will be made to monitor how the body responds and to check for any adverse events, which are unwanted or harmful medical occurrences. Monitoring includes checking vital signs, such as heart rate and blood pressure, and performing an electrocardiogram to check the electrical activity of the heart.

The purpose of this research is to evaluate how safe and well-tolerated AOC 1001 is when used as a long-term treatment for people with Myotonic Dystrophy Type 1. During the study, participants will receive regular infusions of the medication over an extended period. The medication will be administered at a dose based on the participant’s body weight, up to a maximum of 4 mg per kilogram.

This is a continuation study, which means it follows up on previous research with the same medication. The study is “open-label,” which means all participants will receive the active medication, and there is no placebo group. The treatment period may last up to 48 weeks, during which participants will receive multiple doses of the study medication while being monitored for any effects or side effects.

Participants in the study will receive either Mexiletine PR or Mexiletine IR over a period of 24 weeks. The study is designed as an open-label, randomized, cross-over trial, meaning that participants will switch between the two forms of the medication during the study. This approach helps researchers compare the effects of each medication form directly. The study will monitor the occurrence of any side effects and how well participants tolerate the medications. Additionally, the study will assess improvements in muscle stiffness and overall quality of life using various tests and questionnaires.

The primary focus is on the safety of the medications, looking at any adverse events that may occur during the treatment period. Secondary measures include video recordings of hand movements, quality of life assessments, and other tests to evaluate the impact of the medications on daily activities. The study aims to provide valuable information on the best treatment approach for managing symptoms in individuals with non-dystrophic myotonias.

The purpose of the study is to evaluate how safe and effective Mexiletine is when used over a long period. Participants in the study will take the medication once daily. The study will monitor any side effects and how well the medication helps with symptoms like muscle stiffness. Participants will also undergo regular health checks, including physical exams and heart monitoring, to ensure their safety throughout the study.

This study is an extension of a previous study, meaning it continues to follow patients who have already been taking Mexiletine to gather more information about its long-term use. The study will last for up to 18 months, during which participants will be regularly assessed to track their progress and any changes in their condition. The goal is to provide valuable insights into the long-term management of Myotonic Dystrophy with Mexiletine.

The purpose of this study is to evaluate how effective and safe Mexiletine is in treating the symptoms of myotonia, which is the delayed relaxation of muscles after contraction, in patients with Myotonic Dystrophy. Participants in the study will take the medication once daily for a period of 26 weeks. Throughout the study, various assessments will be conducted to monitor changes in muscle function and overall quality of life. These assessments include measuring handgrip relaxation time and using questionnaires to evaluate the impact of the condition on daily life.

Participants will be randomly assigned to receive either the Mexiletine treatment or a placebo, and neither the participants nor the researchers will know which treatment each participant is receiving. This approach is known as a double-blind study and helps ensure that the results are unbiased. The study aims to provide valuable information on whether Mexiletine can be a beneficial treatment option for individuals living with Myotonic Dystrophy.

The purpose of this study is to find out if ARO-DM1 is safe and well-tolerated in people with Type 1 Myotonic Dystrophy, and to understand how the body processes the medicine and how it affects the disease. The study will also look at whether the medicine can improve the condition in some participants. This is a dose-escalating study, which means that different groups of participants will receive different amounts of the medicine to find the best dose. The study will measure how often side effects occur and how severe they are, as well as how the medicine moves through the bloodstream over time.

Participants in this study will be adults between 18 and 65 years old who have a confirmed genetic diagnosis of the condition with a specific genetic pattern. They must have visible signs of muscle stiffness and be able to walk independently for at least 10 meters, though they may use braces. The study involves receiving either the study medicine or placebo through infusions, and participants will be monitored throughout the study period for safety and how well the treatment works.

The purpose of this study is to evaluate how safe and tolerable VX-670 is for patients over an extended period. Participants in the study will receive the treatment and be monitored for any side effects or changes in their health. The study will also look at how the body processes the treatment and its effects on the disease. This includes checking for any changes in muscle tissue and the presence of the treatment in the blood and muscles.

Throughout the study, participants will have regular check-ups to monitor their health, including assessments of vital signs, heart function through electrocardiograms (ECGs), and laboratory tests. The study aims to provide valuable information on the long-term use of VX-670 for managing Myotonic Dystrophy Type I, helping to understand its potential benefits and any risks involved.

The purpose of the study is to evaluate how effective AOC 1001 is in improving hand function in people with Myotonic Dystrophy Type 1. Participants in the study will receive either the AOC 1001 treatment or a placebo, which is a substance with no active medication. The study will last for a period of 54 weeks, during which participants will have regular visits to monitor their progress and assess any changes in their condition.

Throughout the study, researchers will focus on measuring changes in hand function, as well as other aspects of muscle strength and daily activities. The goal is to determine if AOC 1001 can help improve the quality of life for those living with Myotonic Dystrophy Type 1. Participants will be closely monitored to ensure their safety and to gather important information about the treatment’s effects.

The study is divided into two parts. In the first part, participants will receive single doses of VX-670 to determine how well it is tolerated. In the second part, both single and multiple doses will be given to further evaluate safety and tolerability. Some participants will receive a placebo, which is a substance with no active medication, to compare the effects of VX-670.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This will include regular check-ups, laboratory tests, and assessments of heart function using standard tests like electrocardiograms (ECGs). The study aims to gather important information about how VX-670 is processed in the body and its potential impact on muscle function in individuals with Myotonic Dystrophy Type 1.

The purpose of the study is to evaluate how well metformin works in improving muscle function in patients with Myotonic Dystrophy Type 1. Participants in the study will be randomly assigned to receive either metformin or a placebo. The study will last for about 12 months, during which participants will have regular check-ups to monitor their muscle function and overall health. The study will also assess the safety of metformin by keeping track of any serious side effects that may occur during the treatment period.

Throughout the study, various aspects of muscle function will be measured, including walking ability, hand-grip strength, and other physical capabilities. The study will also look at how metformin affects heart and lung function, as well as the overall quality of life for participants. By the end of the study, researchers hope to determine whether metformin can be a beneficial treatment for improving muscle function in people with Myotonic Dystrophy Type 1.

Participants in the study will receive either the ATX-01 treatment or a placebo. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. The study will involve both single and multiple doses of the treatment, administered intravenously, which means it will be given directly into a vein. The trial will include regular monitoring to ensure the safety of participants and to observe any effects of the treatment.

The study aims to gather information on how the body processes ATX-01 and its potential effects on the symptoms of Myotonic Dystrophy Type 1. Participants will be monitored for any side effects, and various health parameters will be assessed throughout the study. The trial is expected to provide valuable insights into the potential benefits and risks of ATX-01 for individuals with DM1.